EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Beyond Transposons: TIGD1 as a Pan-Cancer Biomarker and Immune Modulator

Merve Gulsen Bal Albayrak iD, Tuğcan Korak iD, Gurler Akpinar, Murat Kasap

Genes · 2025

DOI: 10.3390/genes16060674 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes, 2025. Verfasst von Merve Gulsen Bal Albayrak und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biology, Faculty of Medicine, Kocaeli University, Kabaoglu District, Baki Komsuoglu Blvd. No:21, Umuttepe, 41001 Kocaeli, Turke…. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Neoplasms. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: TIGD1 (Trigger Transposable Element Derived 1) is a recently identified oncogene with largely unexplored biological functions. Emerging evidence suggests its involvement in multiple cellular processes across cancer types. This study aimed to perform a comprehensive pan-cancer analysis of TIGD1 to evaluate its expression patterns, diagnostic utility, prognostic value, and association with immunotherapy response and drug resistance.

Methods

Transcriptomic and clinical data from TCGA and GTEx were analyzed using various bioinformatic tools. Expression profiling, survival analysis, immune correlation studies, gene set enrichment, single-cell sequencing, and drug sensitivity assessments were performed.

Results

TIGD1 was found to be significantly upregulated in various tumor types, with notably high expression in colon adenocarcinoma. Elevated TIGD1 expression was associated with poor prognosis in several cancers. TIGD1 levels correlated with key features of the tumor immune microenvironment, including immune checkpoint gene expression, TMB, and MSI, suggesting a role in modulating anti-tumor immunity. GSEA and single-cell analyses implicated TIGD1 in oncogenic signaling pathways. Furthermore, high TIGD1 expression was linked to resistance to several therapeutic agents, including Zoledronate, Dasatinib, and BLU-667.

Conclusions

TIGD1 may serve as a promising diagnostic and prognostic biomarker, particularly in colon, gastric, liver, and lung cancers. Its strong associations with immune modulation and therapy resistance highlight its potential as a novel target for precision oncology and immunotherapeutic intervention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorNeoplasmsHumansGene Expression Regulation, NeoplasticPrognosisTumor MicroenvironmentDNA Transposable ElementsDrug Resistance, NeoplasmTranscriptome

Stichwörter der Autor:innen

TIGD1cancer prognosisdrug resistanceimmune microenvironmentimmunotherapymicrosatellite instabilitypan-cancer analysistumor mutational burden

Substanzen

Biomarkers, TumorDNA Transposable Elements

Autor:innen und Institutionen

  • Department of Medical Biology, Faculty of Medicine, Kocaeli University, Kabaoglu District, Baki Komsuoglu Blvd. No:21, Umuttepe, 41001 Kocaeli, Turkey.

ORCID-Profile: Merve Gulsen Bal Albayrak, Tuğcan Korak

Zitieren

APA

Bal Albayrak, M. G., Korak, T., Akpinar, G., & Kasap, M. (2025). Beyond Transposons: TIGD1 as a Pan-Cancer Biomarker and Immune Modulator. Genes. https://doi.org/10.3390/genes16060674

Vancouver

Bal Albayrak MG, Korak T, Akpinar G, Kasap M. Beyond Transposons: TIGD1 as a Pan-Cancer Biomarker and Immune Modulator. Genes. 2025. doi:10.3390/genes16060674

BibTeX
@article{BalAlbayrak2025,
  author = {Bal Albayrak, Merve Gulsen and Korak, Tuğcan and Akpinar, Gurler and Kasap, Murat},
  title = {Beyond Transposons: TIGD1 as a Pan-Cancer Biomarker and Immune Modulator},
  journal = {Genes},
  year = {2025},
  doi = {10.3390/genes16060674}
}
Kostenlos starten →